title: Bioavailability of temazepam: comparison of four 7.5-MG capsules with a single 30-MG capsule.
abstract: OBJECTIVE
  To compare the bioavailability of four temazepam 7.5-mg capsules (Restoril, Sandoz Pharmaceuticals) with that of a single temazepam 30-mg capsule.
  
  
  METHODS
  Single-dose, open-label, two-period, crossover (replicated Latin square).
  
  
  METHODS
  Domiciled environment for clinical testing.
  
  
  METHODS
  Twenty-six healthy male volunteers aged 18-40 years; 25 completed the study.
  
  
  METHODS
  Subjects randomly received either four temazepam 7.5-mg capsules or one temazepam 30-mg capsule. Blood samples were drawn at various time points after each period (0-48 h), and analyzed for plasma concentration of temazepam. The washout period between doses was five days.
  
  
  METHODS
  Five parameters of both dosage forms were compared: (1) area under curve (AUC), (2) peak concentration (Cmax), (3) time to peak concentration (Tmax), (4) apparent rate constant for absorption, and (5) lag time for appearance of drug in plasma. Statistical procedures included ANOVA, power analysis, and confidence limits.
  
  
  RESULTS
  The mean AUC for the four 7.5-mg capsules and one 30-mg capsule differed by less than 2 percent and the mean Cmax differed by less than 14 percent for the two dosage strengths; neither of these differences reached statistical significance (p > 0.05). The 7.5-mg capsules reached peak plasma concentrations significantly faster than the 30-mg dosage form (mean Tmax 1.18 and 1.73 h, respectively; p = 0.01).
  
  
  CONCLUSIONS
  The two formulations of temazepam were bioequivalent with respect to the extent of bioavailability. Regarding the rate of absorption, however, the 7.5-mg capsules reached peak plasma concentrations significantly faster than the 30-mg dosage form.
authors.affiliation: Drug Metabolism Department, Sandoz Research Institute, East Hanover, NJ 07936.
authors.forename: C
authors.initials: C
authors.lastname: Abolin
authors.forename: D S
authors.initials: DS
authors.lastname: Hwang
authors.forename: F
authors.initials: F
authors.lastname: Mazza
mesh_terms: D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D002214:Capsules; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D013693:Temazepam / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
chemical_list: D002214:Capsules; D013693:Temazepam